Potassium channel openers antagonize the effects of class III antiarrhythmic agents in canine Purkinje fiber action potentials. Implications for prevention of proarrhythmia induced by class III agents

Japanese Heart Journal

Volumn 40, Issue 5, 1999, Pages 609-619

  Kondo, Masahiko ^a,b   Tsutsumi, Takeshi ^a   Mashima, Saburo ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

Class III antiarrhythmic agents; Early afterdepolarization; Potassium channel opener; Reverse frequency dependence; Triggered activity

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 4 (N ACETYL N HYDROXYAMINO) 6 CYANO 3,4 DIHYDRO 2,2 DIMETHYL 2H 1 BENZOPYRAN 3 OL; ANTIARRHYTHMIC AGENT; DOFETILIDE; NICORANDIL; POTASSIUM CHANNEL STIMULATING AGENT;

ACTION POTENTIAL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DOG; DOSE RESPONSE; MEMBRANE STEADY POTENTIAL; MICROELECTRODE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PURKINJE FIBER;

EID: 0032803378     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/jhj.40.609     Document Type: Article

References (16)

1. Jackman W, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115-72.
2. Longman SD, Hamilton TC. Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev 1992; 12: 73-148.
3. Knight C, Purcell H, Fox K. Potassium channel openers: clinical applications in ischemic heart disease-overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 1995; 9: 229-236.
4. Harverkamp W, Borggrefe M, Breithardt G. Electrophysiologic effects of potassium channel openers. Cardiovasc Drugs Ther 1995; 9: 195-202.
5. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. Circ Res 1985; 56: 857-67.
6. Fish FA, Prakash C, Roden DM. Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators. Circulation 1990; 82: 1362-9.
7. Carlsson L, Abrahamsson C, Drews L, Duker G. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delay repolarization. Circulation 1992; 85: 1491-500.
8. Kasama M, Tsutsumi T, Miyamoto N, Mashima S. Suppressive effects of nicorandil on early afterdepolarization induced by class III antiarrhythmic drugs. Ther Res 1993; 14: 137-41.
9. + current by dofetilide. Circ Res 1993; 72: 75-83.
10. + channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state. J Pharmacol Exp Ther 1992; 261: 730-6.
11. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Circulation 1990; 81: 686-90.
12. + current by almokalant in rabbit ventricular myocytes. Circ Res 1993; 73: 857-68.
13. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr: implications for Torsade de Pointes and reverse use-dependence. Circulation 1996; 93: 407-11.
14. + Channels in Cardiovascular Medicine. Paris, France: Springer-Verlag, 1993: 41-53.
15. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM for the SADS Foundation Task Force on LQTS. Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions. Circulation 1996; 94: 1996-2012.
16. El-Sherif N, Chinushi M, Caref EB, Restivo M. Electrophysiological mechanism of the characteristic electrocardiographic morphology of Torsade de Pointes tachyarrhythmias in the long-QT syndrome; detailed analysis of ventricular tridimensional activation patterns. Circulation 1997; 96: 4392-9.